Healthy Clinical Trial
Official title:
Assessment of Renal Artery Stenosis and Renovascular Hypertension by Contrast Enhanced Magnetic Resonance Imaging: A Pilot Study
Renovascular hypertension (RVH) is a potentially curable disease affecting 0.5-5 percent of
patients with hypertension. The current diagnostic work-up of RVH involves a complex
algorithm which includes doppler ultrasound, captopril renography and conventional
angiography. Because of the expense, risk and inconvenience of this workup, patients may not
be correctly diagnosed.
Advances in MR technology present the opportunity to develop a single comprehensive test.
This would combine an MR angiogram that provides anatomic information about the renal
arteries, and an MR renogram that provides information about the functional impact of a
stenosis as a cause of hypertension. Our main purpose is to test MR renography with and
without an oral angiotensin converting enzyme inhibitor (ACEI) combined with MR angiography
against the reference standard of captopril radionuclide renography. Secondary goals of this
study are to test whether hypoxia within ischemic kidneys affected by RVH is detectable by
T2 weighted (Blood oxygen level dependent or BOLD) MRI. This is considered of value since
such a test of oxygenation would further shorten and simplify the diagnostic MR test.
Information gained from this study could lead to important changes in the diagnostic and
pathophysiologic understanding of RVH.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 2004 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA Healthy volunteers or patients with significant clinical suspicion of renovascular hypertension. Subjects able to understand the informed consent for this study. Subjects must be able to hold their breath for 20 second intervals. Patients must be clinically stable and be judged by their physician able to tolerate the MR study of 1.5-2 hour duration. EXCLUSION CRITERIA Any contraindication for MR study including: pacemaker or other implanted electronic device; cochlear implants; metal in the eye; embedded shrapnel fragments; cerebral aneurysm clips; or medical infusion pumps. Allergy to gadolinium, iodinated contrast media, ACEIs, or sulphur-containing medication. Patients have a hematocrit at or below 30. Severe anemia may predispose to hypotension after captopril. Patients with hyperkalemia (plasma potassium: above 5.0 mmol/L), because of the risk of arrhythmia. Clinically unstable patients and those unable to tolerate a 1-2 hour MR study. Examples of medical conditions that would lead to exclusion include unstable angina, dyspnea at rest, severe pain at rest, or severe back pain. Pregnancy. Nursing mothers. Subjects who are claustrophobic and are unable to tolerate MR imaging. Patients with a serum creatinine concentration above 4mg/dl. Bilateral renal stents. Healthy subjects must not have an abnormality detected on dipstick urinalysis, or a systolic BP above 140 mmHg or a diastolic BP above 90 mmHg on screening examination or an abnormal BUN or creatinine level in the blood. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | Warren G. Magnuson Clinical Center (CC) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institutes of Health Clinical Center (CC) |
United States,
Bouyounes BT, Libertino JA. Renovascular hypertension. Curr Opin Urol. 1999 Mar;9(2):111-4. Review. — View Citation
Kulkarni S, O'Farrell I, Erasi M, Kochar MS. Stress and hypertension. WMJ. 1998 Dec;97(11):34-8. Review. — View Citation
Taylor A. Radionuclide renography: a personal approach. Semin Nucl Med. 1999 Apr;29(2):102-27. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |